Novo Nordisk faced competing narratives over the past 30 days as fundamental strength collided with market skepticism. The company delivered solid Q2 results with adjusted operating profit of DKK 33.4 billion and raised full-year guidance for the second consecutive time, yet the stock declined 28%, creating what analysts described as a valuation paradox highlighting market concerns beyond operational execution. The dominant catalyst was escalating litigation with Eli Lilly over GLP-1 marketing practices, signaling commercial rivalry shifting to courtroom confrontation. This lawsuit coincided with a clinical setback in heart drug development that rippled across the anti-inflammatory therapeutic class, creating credibility concerns for Novo's pipeline beyond obesity. Manufacturing capacity emerged as the new competitive moat in the $100 billion obesity market, with both Lilly and Novo investing heavily in production infrastructure. Supply constraints and U.S. drug manufacturing policy shifts created a strategic inflection point. The neutral 0.63 grade score reflects market participants prioritizing supply-chain execution over near-term financial performance.